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Background:  COURAGE trial showed that as an initial management strategy in selected patients with stable coronary artery disease, PCI did 
not reduce the risk of death or myocardial infarction when added to optimal medical therapy (OMT). We assessed the hypothesis that real-world 
treatment of “COURAGE-like” patients is far from the statements of that trial.
Methods:  From November 2009 to May 2010 we evaluated prospectively and consecutively all patients admitted to the catheterization lab in 
four hospitals in Buenos Aires with an indication of coronary angiography because of stable coronary syndrome. After performing the angiography 
we selected the patients using the same inclusion and exclusion criteria of COURAGE trial. We assessed the medical treatment and contacted their 
cardiologist in order to let them decide to perform a PCI or continue medical treatment alone.
Results:  274 patients with the same inclusion and exclusion criteria of COURAGE trial were included in our analysis. Patients’ characteristics were: 
average age 64 y/o, male 66%, hypertension 86%, diabetes 21%, dyslipidemia 90%. Angina according to de CCS was 0 38%, I 19%, II 38% and III 
5%. 90% of them had a positive stress test. Only 21% of patients received all the drugs suggested for the COURAGE trial defined as OMT (Aspirin 
and/or Clopidogrel 97%, `-blockers 68%, calcium channel blockers 26%, ACEI or ARBS 63%, nitrates 30%, statins 88%) and only 33% of them (7% 
of the total of the patients) reached the treatment targets (BP <130/85 mmHg 55%, LDL <85 mg/dl 18%, HDL >40 mg/dl 47%, triglycerides <150 
mg/dl 74%, HbA1c <7% in diabetic patients 20%). In 96% of the patients their cardiologist indicated to perform a PCI and only 4% decided to 
continue medical treatment alone.
Conclusions:  Despite the results of COURAGE trial, only a minority of patient COURAGE-like were on OMT and almost all of them were sent for 
their cardiologist to perform a PCI.
